1.25 semaglutide Oral Wegovy approved for obesity management by FDA on December 23, 2025 Formulation: High‑dose oral (25 mg daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) and reduced Semaglutide diabetes medication packag |

Operationally, Mochi experienced a tumultuous period in the spring of 2025

Eli Lilly, the firm that makes Mounjaro, said patient safety was its "top priority", adding that it actively reports safety information to the MHRA and encourages "healthcare professionals and others" to do the same via the Yellow Card scheme

Over time, the dosage can be increased to help achieve the best possible weight loss and blood sugar control results

Please enter your contact details below and the reason for your discovery call and we will get back to you to arrange a suitable time for your FREE 15 Minute Discovery Call

It aids your digestion, helps you to regulate mood, and assists in maintaining a healthy immune system